Browse the evidence

GLP-2 analogs are effectively used in the management of short bowel syndrome, reducing the need for parenteral support and improving patient quality of life.

For patients with short bowel syndrome, GLP-2 analogs are an effective treatment that can reduce the need for intravenous nutrition (parenteral support) and improve quality of life.

Glucagon remains essential for emergency hypoglycemia treatment.

Glucagon is an essential emergency treatment for severe hypoglycemia. Patients at risk should have access to glucagon kits and be trained in their use to ensure rapid and effective treatment of low blood sugar episodes.

Empagliflozin (10 mg/day) does not significantly reduce the primary composite endpoint of hospitalization for heart failure or death from any cause in patients hospitalized with acute myocardial infarction.

Empagliflozin (10 mg daily) did not significantly reduce the risk of heart failure hospitalization or death in patients recently hospitalized for a heart attack, according to the EMPACT-MI trial. However, secondary analyses suggested some benefits in reducing heart failure events.

A 12-week treatment with dulaglutide (1.5 mg weekly) does not improve long-term smoking abstinence rates compared to placebo when used as an adjunct to standard cessation therapy.

If you are trying to quit smoking, taking dulaglutide (Trulicity) alongside standard treatment (like Chantix/varenicline) will not increase your chances of staying smoke-free compared to standard treatment alone. Do not expect dulaglutide to help you quit smoking.

Obesity is a chronic disease driven by hypothalamic dysregulation of body fat mass set points, not by individual neglect of eating habits or exercise.

Stop blaming yourself for your weight. Your body is biologically defending a higher fat mass set point due to hypothalamic dysregulation. This is a chronic disease, not a moral failing. Effective treatment requires addressing this biology (e.g., via medications or surgery that target these pathways) rather than relying solely on willpower or calorie counting, which often fail because they trigger metabolic adaptation.

SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with type 2 diabetes, regardless of baseline ejection fraction or diabetes status.

If you have Type 2 Diabetes and Heart Failure (or are at high risk), ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga). These drugs are proven to significantly reduce the risk of being hospitalized for heart failure and dying from cardiovascular causes, regardless of your heart's pumping ability. They are now considered a standard part of treatment for this condition.

Resmetirom is the first FDA-approved drug for treating noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, demonstrating efficacy in resolving NASH without worsening fibrosis and improving fibrosis by at least one stage without worsening NASH.

Resmetirom is now the first approved medication for NASH with fibrosis. It works by targeting thyroid hormone receptors to reduce liver fat and inflammation. Patients should discuss eligibility, specifically regarding fibrosis stage, with their healthcare provider, keeping in mind the high cost and the need for ongoing monitoring.

Thiazolidinediones (TZDs) increase the risk of hospitalization for heart failure through fluid retention mediated by sodium reabsorption.

If you have Type 2 Diabetes and Heart Failure, especially if it is moderate to severe (NYHA class III or IV), you should likely avoid Thiazolidinediones (like Actos or Avandia). These drugs cause fluid retention and significantly increase the risk of being hospitalized for heart failure. Your doctor will likely choose a different medication.

Females exhibit higher GLP-1 receptor (GLP1R) expression in specific brain regions (PBN, AP/NTS) involved in processing aversive stimuli, which may explain their heightened sensitivity to GLP-1 agonist-induced nausea.

This finding suggests that women's brains may have more 'targets' for GLP-1 drugs in areas that control nausea, which is why side effects are more common. This is a biological fact, not a personal failing.

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) significantly slow the progression of diabetic kidney disease (DKD) and reduce cardiovascular events in patients with chronic kidney disease (CKD), regardless of baseline glycemic control or diabetes status.

If you have diabetes and kidney disease (or high cardiovascular risk), ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga, or Trjendi). These drugs protect your kidneys and heart, even if your blood sugar is already well-controlled. They are taken once daily. Be aware of potential genital yeast infections or, rarely, ketoacidosis, but these risks are generally manageable and outweighed by the protection they offer to your kidneys.

Sibutramine, a serotonin-norepinephrine reuptake inhibitor, was withdrawn from the European market because it significantly increases the risk of serious cardiovascular events (stroke, heart attack, cardiac arrest) without providing sufficient long-term benefit.

Sibutramine is no longer available in Europe because it was found to increase the risk of heart attacks and strokes. If you encounter it in illicit products imported from outside the EU, be aware that these products may be unsafe and unregulated. Always inform your doctor about any weight loss supplements you are taking.

GLP-1 receptor agonists induce nausea and vomiting primarily by binding to GLP-1 receptors in the dorsal vagal complex (brainstem) and stimulating peripheral vagal nerve fibers, leading to delayed gastric emptying and increased gut-to-brain signaling.

Nausea from GLP-1 medications is not a sign of toxicity or damage. It is a predictable side effect caused by how the drug interacts with your brain and gut nerves. This is why starting with a low dose helps your body adapt. The feeling is temporary and manageable, and it does not mean the medication is harming you.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce the risk of hospitalization for heart failure in patients with type 2 diabetes, independent of glycemic control.

If you have Type 2 Diabetes and are at risk for heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs have been proven in large studies to significantly lower the risk of hospitalization for heart failure, even independent of their blood sugar-lowering effects. This is a key preventive strategy for heart health in diabetes.

Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces cardiovascular and renal risks in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and kidney disease, adding finerenone to your current treatment can significantly lower your risk of heart problems and kidney failure. It is designed to avoid the side effects of older medications in its class.

Historical obesity pharmacotherapies utilizing thyroid hormones, sympathomimetics, and serotonergic agents were withdrawn due to severe cardiovascular, psychiatric, or oncological toxicity, despite demonstrating weight loss efficacy.

Do not use historical weight loss drugs like thyroid hormones, amphetamines, or fenfluramine. They are dangerous and have been withdrawn from the market due to severe side effects like heart damage and death. Modern treatments focus on safer mechanisms like GLP-1 agonists.

There is no head-to-head evidence to determine which drug class (THR-β vs Incretins) is superior for histological outcomes in MASH.

Both resmetirom and incretins work for MASH, but we don't know which is better for the liver itself because no study has compared them directly.

There were no reported hospitalizations from severe hypoglycemia or diabetic ketoacidosis in the treated group.

The safety profile suggests that tirzepatide may be a safe option for managing T1D in this population.

There is a strong correlation between online search trends and prescriptions for semaglutide (Wegovy) with a correlation coefficient of r = 0.97.

Monitoring online search trends can provide insights into public interest in obesity medications.

Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased incidence of diabetic retinopathy (DR) with a hazard ratio (HR) of 1.07 (95% CI, 1.03-1.11).

Clinicians should be aware of the increased risk of DR when prescribing GLP-1 RAs to patients with T2D.

GLP-1 RAs are not associated with progression to proliferative diabetic retinopathy (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) in patients with preexisting DR.

Patients with preexisting DR may not experience worsening of certain complications when treated with GLP-1 RAs.

In patients with cardiometabolic HFpEF, semaglutide showed a 42% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Semaglutide may be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

GIP antagonism has been shown to reduce the development of obesity in preclinical models.

GIP antagonism could be a potential strategy for obesity treatment.

The effect of linolenic acid on food intake and body mass disappears in mice lacking the GDF15 receptor GFRAL.

The presence of the GFRAL receptor is essential for the appetite-suppressing effects of linolenic acid.

Manufacturer discounts for GLP1s approved for obesity were estimated at 41%, resulting in net prices of $717 to $761 per month of supply.

Practitioners should consider the significant discounts when discussing GLP1s with patients.